- Home
- ZNTL vs GAMB Comparison
ZNTL vs GAMB Comparison
Compare ZNTL & GAMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- GAMB
- Stock Information
- Founded
- ZNTL 2014
- GAMB 2006
- Country
- ZNTL United States
- GAMB Jersey
- Employees
- ZNTL N/A
- GAMB N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- GAMB Services-Misc. Amusement & Recreation
- Sector
- ZNTL Health Care
- GAMB Consumer Discretionary
- Exchange
- ZNTL Nasdaq
- GAMB Nasdaq
- Market Cap
- ZNTL 238.2M
- GAMB 357.3M
- IPO Year
- ZNTL 2020
- GAMB 2021
- Fundamental
- Price
- ZNTL $3.12
- GAMB $9.85
- Analyst Decision
- ZNTL Buy
- GAMB Strong Buy
- Analyst Count
- ZNTL 7
- GAMB 4
- Target Price
- ZNTL $10.86
- GAMB $13.25
- AVG Volume (30 Days)
- ZNTL 1.2M
- GAMB 86.7K
- Earning Date
- ZNTL 11-04-2024
- GAMB 11-14-2024
- Dividend Yield
- ZNTL N/A
- GAMB N/A
- EPS Growth
- ZNTL N/A
- GAMB 445.61
- EPS
- ZNTL N/A
- GAMB 0.67
- Revenue
- ZNTL $40,560,000.00
- GAMB $115,744,000.00
- Revenue This Year
- ZNTL N/A
- GAMB $17.13
- Revenue Next Year
- ZNTL N/A
- GAMB $11.30
- P/E Ratio
- ZNTL N/A
- GAMB $14.77
- Revenue Growth
- ZNTL N/A
- GAMB 23.58
- 52 Week Low
- ZNTL $2.83
- GAMB $7.52
- 52 Week High
- ZNTL $18.24
- GAMB $13.88
- Technical
- Relative Strength Index (RSI)
- ZNTL 44.34
- GAMB 48.46
- Support Level
- ZNTL $2.92
- GAMB $9.75
- Resistance Level
- ZNTL $3.23
- GAMB $10.06
- Average True Range (ATR)
- ZNTL 0.17
- GAMB 0.19
- MACD
- ZNTL 0.00
- GAMB -0.01
- Stochastic Oscillator
- ZNTL 38.33
- GAMB 65.15
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses a drug discovery engine, which it refers to as an Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. It has two lead product candidates under pipeline: ZN-c5, for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer; and ZN-c3, for the treatment of advanced solid tumors as monotherapy and ovarian cancer.
About GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casino and online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.